IP Verse

Gilead Sciences competitive analysis

Latest oppositions filed by Gilead Sciences

Explore patent oppositions filed by Gilead Sciences against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP3854403
Use Of Substituted Aminopropionate Compounds In Treatment Of Sars-Cov-2 InfectionACADEMY OF MILITARY MEDICAL SCIENCESJun 18, 2025
EP2399588
Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral PolymeraseIONIS PHARMACEUTICALSJan 7, 2021
EP3284520
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIFeb 4, 2020
EP2955190
Chemical CompoundsNUCANADec 17, 2018
EP3045206
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIDec 6, 2018
EP1576138
2-Branched Nucleosides And Flaviviridae MutationIDENIX CAYMANOct 31, 2017
EP2332952
Modified 2' And 3'-Nucleoside Prodrugs For Treating Flaviridae InfectionsCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSJan 28, 2016

Latest patents of Gilead Sciences opposed by its competitors

Explore Gilead Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3321270
Dec 4, 2024Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-Olate5
EP4233846
Dec 4, 2024Pharmaceutical Formulations3
EP2487161
Jun 5, 2024Modulators Of Pharmacokinetic Properties Of Therapeutics2
EP2049506
May 8, 2024Modulators Of Pharmacokinetic Properties Of Therapeutics3
EP3595667
Dec 20, 2023Pharmaceutical Compositions Comprising A Jak Inhibitor3
EP2744810
Sep 13, 2023Tenofovir Alafenamide Hemifumarate3
EP2655623
Aug 30, 2023Non-Coding Immunomodulatory Dna Construct1
EP4070788
Mar 22, 2023Pharmaceutical Formulations1
EP4070787
Mar 1, 2023Pharmaceutical Formulations1
EP2640362
Dec 1, 2021Therapeutic Compositions Comprising Rilpivirine Hcl And Tenofovir Disoproxil Fumarate2

Latest PTAB cases involving Gilead Sciences

Discover the latest PTAB cases involving Gilead Sciences, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 28, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Gilead Sciences

IPR2025-00033Oct 28, 2024CIPLAGILEAD SCIENCESInstitution Denied
PGR2023-00046Aug 7, 2023ATEA PHARMACEUTICALSGILEAD SCIENCESInstitution Denied
IPR2019-01455Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01456Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01453Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01454Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2017-02005Aug 29, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-02004Aug 28, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-02004Aug 28, 2017GILEAD SCIENCESWAGNERInstitution Denied
IPR2017-01753Jul 7, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Gilead Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GILEAD SCIENCES75986
COOKE37 - - 4
SANDOZ1462619 -
TEVA PHARMACEUTICAL INDUSTRIES LTD2657 - -